Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$95.36
-$1.30(-1.34%)
At close: 4:00 PM EDT
$95.36
-$1.30(-1.34%)
Day’s Range― - ―
52-Week Range$28.66 - $97.63
Previous CloseN/A
Volume1.00M
Average Volume (3M)1.06M
Market Cap
$10.11B
Enterprise Value$3.88K
Total Cash (Recent Filing)$308.20M
Total Debt (Recent Filing)$9.42M
Price to Earnings (P/E)209.3
Beta0.55
Next Earnings
Nov 04, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding107,351,590
10 Day Avg. Volume1,209,033
30 Day Avg. Volume1,056,039
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$122.60Price Target Upside28.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.75
Revenue Forecast (FY)$999.54M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable equity base give durable financial flexibility to fund launches, trials or M&A. This reduces bankruptcy and refinancing risk, supports sustained R&D/commercial investment, and preserves optionality through multi-year development timelines.
Healthy Cash GenerationStrong cash conversion means earnings are largely cash-backed, enabling the company to self-fund launch and development programs without immediate reliance on external financing. Even with cooled trends, positive FCF supports multi-year commercial scale-up and pipeline funding.
Diversifying Commercial & Clinical MomentumLifyorli's compelling survival benefit and quick uptake materially diversify revenue beyond Korlym and expand addressable markets. Coupled with relacorilant resubmission and multiple oncology/neurology readouts, the pipeline materially increases long-term revenue optionality and strategic reach.
Bears Say
Profitability CompressionMargins have meaningfully eroded due to elevated launch and operating spend and temporary patient access issues. Sustained profitability recovery requires continued strong product uptake and successful mitigation of payer/operational headwinds, creating medium-term earnings risk.
Revenue ConcentrationHistorically dependent on a single legacy product, the company remains exposed to payer, competitive, or regulatory shifts until new approvals scale. Early oncology revenues help, but durable diversification is contingent on sustained Lifyorli uptake and additional approvals.
Ongoing Legal OverhangAn active qui tam suit creates multi-year litigation risk, potential settlement exposure, and reputational/regulatory distraction. Even without DOJ intervention now, prolonged legal proceedings can divert management, increase costs, and affect payer or partner willingness over several quarters.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $97.63 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $10.11B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 96 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Jul 29, 2026. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.024 by $0.336.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.65.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.36 in its last earnings report, beating expectations of $0.024. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$122.60 (28.57% Upside)
$122.60 (28.57% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$122.60
▲(28.57% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.87% Insiders
15.08% Mutual Funds
1.07% Other Institutional Investors
51.71% Public Companies and Individual Investors